Article Details

Applied DNA Subsidiary, LineaRx Signs Joint Development Agreement with Takis and Evvivax

Retrieved on: 2018-09-19 17:56:15

Tags for this article:

Click the tags to see associated articles and topics

Applied DNA Subsidiary, LineaRx Signs Joint Development Agreement with Takis and Evvivax. View article details on hiswai:

Excerpt

<div><b>Applied DNA Sciences</b> (NASDAQ:APDN) announced that LineaRx its wholly-owned subsidiary focused on next-generation biotherapeutics, has ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo